argenx SE
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARGNF research report →
Companywww.argenx.com
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases.
- CEO
- Timothy Van Hauwermeiren
- IPO
- 2015
- Employees
- 1,599
- HQ
- Breda, NL
Price Chart
Valuation
- Market Cap
- $49.70B
- P/E
- 43.65
- P/S
- 14.70
- P/B
- 6.73
- EV/EBITDA
- 47.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.00%
- Op Margin
- 25.64%
- Net Margin
- 33.42%
- ROE
- 16.82%
- ROIC
- 11.74%
Growth & Income
- Revenue
- $4.32B · 97.25%
- Net Income
- $1.34B · 61.41%
- EPS
- $21.94 · 57.61%
- Op Income
- $1.01B
- FCF YoY
- 1136.04%
Performance & Tape
- 52W High
- $872.27
- 52W Low
- $532.40
- 50D MA
- $774.59
- 200D MA
- $803.20
- Beta
- -0.06
- Avg Volume
- 2
Get TickerSpark's AI analysis on ARGNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ARGNF Coverage
We haven't published any research on ARGNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARGNF Report →